Insights from 2023 ESMO Annual Meeting
ESMO 2023 Insights: "Durable Efficacy of Zenocutuzumab, a HER2 x HER3 Bispecific Antibody, in Advanced NRG1+ NSCLC"
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Alison Schram
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Alison Schram
Login to view comments.
Click here to Login
